Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA7 | P43166 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 3/20 | 0.37 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL642078 | 0.79 | CA12 (0.42) | CA12CA1CA2CA7CA9 | |
| SCHEMBL642932 | 0.77 | CA12 (0.43) | CA12CA1CA2CA7CA9 | |
| SCHEMBL692586 | 0.75 | CA12 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL644036 | 0.74 | TSHR (0.43) | CA12CA1CA2CA7CA9 | |
| SCHEMBL644740 | 0.73 | CA12 (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL26412235 | 0.73 | HTT (0.45) | CA12CA1CA2CA7CA9 | |
| SCHEMBL19436185 | 0.72 | CA12 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL10394316 | 0.71 | HSD17B2 (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28366323 | 0.71 | NPSR1 (0.42) | CA12CA1CA2CA7CA9 | |
| SCHEMBL24613975 | 0.71 | POLB (0.55) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111225907-B | Process for preparing benzothien-2 yl boric acid/borate | 拜耳制药股份公司 | 2023-05-26 | — | — | CN | disclosed |
| US-20220356194-A1 | PROCESS FOR PREPARING BENZOTHIOPHEN-2YL BORONATE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-11-10 | — | — | US | disclosed |
| US-11274110-B2 | Process for preparing benzothiophen-2yl boronate | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-03-15 | — | — | US | disclosed |
| US-20200339606-A1 | PROCESS FOR PREPARING BENZOTHIOPHEN-2YL BORONATE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-10-29 | — | — | US | disclosed |
| EP-3700894-A1 | PROCESS FOR PREPARING BENZOTHIOPHEN-2YL BORONATE | Bayer Pharma Aktiengesellschaft (DE) | 2020-09-02 | — | — | EP | disclosed |
| CN-111225907-A | Process for preparing benzothien-2-yl boronic acids/borates | 拜耳制药股份公司 | 2020-06-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220356194-A1 | PROCESS FOR PREPARING BENZOTHIOPHEN-2YL BORONATE | BPGM, BRCA1, BRAP | CA12 869/4885CA1 4179/4885CA2 1240/4885 |
| US-20200339606-A1 | PROCESS FOR PREPARING BENZOTHIOPHEN-2YL BORONATE | BPGM, BRCA1, BRAP | CA12 869/4885CA1 4179/4885CA2 1240/4885 |
| US-11274110-B2 | Process for preparing benzothiophen-2yl boronate | BPGM, BRCA1, BRAP | CA12 869/4885CA1 4179/4885CA2 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.